Loading...
Most acid reflux episodes among patients with symptomatic gastroesophageal reflux disease (GERD) are due to transient lower esophageal relaxations (TLESRs). In recent studies, investigators demonstrated that the gamma-aminobutyric acid (GABA)-receptor agonist baclofen inhibits TLESRs in patients with GERD. Researchers in Belgium investigated the effect of baclofen on duodenal reflux and associated reflux symptoms in 16 patients with heartburn or regurgitation that had persisted for at least 3 months during proton-pump-inhibitor (PPI) therapy (omeprazole, 20 mg twice daily). All patients had normal acid exposure but abnormal duodenal reflux exposure (based on Bilitec monitoring) during PPI therapy.
After 14 days, addition of baclofen (startin…